Cytotoxic effects of cladribine and tezacitabine toward HL-60

• Autorzy: Stachnik K. , Grieb P. , Skierski J.S.
• Języki publikacji: EN

Abstrakty

EN

The aim of the study was to determine the relation between the cytotoxic and cytostatic effects of tezacitabine and cladribine on a HL-60 cell line and the time of exposure of cells to these drugs. Cell viability and induction of apoptosis were assessed using flow cytometry methods. Apoptosis was confirmed by direct microscopic observation. Growth inhibition was examined by cell counting. After 24 h incubation tezacitabine was equally or less toxic compared to cladribine. However, toxicity of tezacitabine strongly rose after 48 h incubation leading to massive cell death at doses much lower than those of cladribine. Assessment of the effect of increased exposure time on the clinical efficacy of tezacitabine is indicated.

Słowa kluczowe

EN

tezacitabine; nucleoside analogue; leukemia; flow cytometry; cladribine; cytotoxic effect; HL-60 cell

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2005
• Tom: 52
• Numer: 2
• Opis fizyczny: p.561-565,fig.,ref.

Twórcy

autor

Stachnik K.

• National Institute of Public Health, Warsaw, Poland

autor

Grieb P.

autor

Skierski J.S.

Bibliografia

• Cohen JD, Strock DJ, Teik JE, Katz TB, Marcel PD (1997) Cancer Le 116: 1671–1675.
• Faderl S, Garcia-Manero G, Thomas DA, Cortes J, O’Brien S, Giles FJ, Koller CA, Beran M, Verstovsek S, Kwari M, Ghandi V, Plunke W, Kantarjian HM (2001) Blood 98: 2493.
• Faderl S, Gandhi V, Kantarjian H, Plunke W (2002) In Cancer Chemot Biol Resp Mod. Ann 20. Giaccone G, Schilsky R, Sondel P, eds, pp 37–58. Elsevier Science B.V. Flaherty KT, Stevenson JP, Gallagher M, Giantonio B, Algazy KM, Sun W, Haller DG, O’Dwyer PJ (2003) Cancer 97: 1985–1990.
• Galmarini CM, Mackey JR, Dumontet C (2001) Leukemia 15: 875–890.
• Grieb P, Koronkiewicz M, Skierski JS (2000) Acta Biochim Polon 47: 165–171.
• Grieb P, Kamienowski J, Janisz M, Kusnierczyk P, Kawiak J, Hoser G, Chrapusta SJ (2001) Int J Hematol 74: 421–427.
• Gollard R, Miller WE, Piro LD, Saven A (1997) Leuk Lymphoma 28: 183–185.
• Griffig J, Koob R, Blakley RL (1989) Cancer Res 49: 6923– 6928.
• Karlsson K, Stromberg M, Liliemark J, Delannoy A, Johnson SA, Porwit A, Kimby E, Larfars G, Cristiansen I, Nilsson G, et al. (2002) Br J Haematol 116: 538–548.
• Lauria F, Bocchia M, Maroa G, Raspadori D, Zinzani PL, Rondelli D (1999) Haematologica 84: 22–25.
• Liliemark J (1997) Clin Pharmacokinet 32: 120–131.
• Liliemark J, Juliusson G (1995) Clin Cancer Res 1: 385–390.
• McCarthy JR, Mahews DP, Stemerick DM, Huber EW, Bey P, Lippert BJ, Snyder RD, Sunkara P (1991) J Am Chem Soc 113: 7439–7440.
• Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al. (1991) J Natl Cancer Inst 83: 757–766.
• Piro LD, Carrera CJ, Carson DA, Beutler E (1990) N Engl J Med 322: 1117–1121.
• Robak T, Gora-Tybor J, Krykowski E, Walewski JA, Borawska A, Pluzanska A, Potemski P, Hellmann A, Zaua JM, Konopka L, et al. (1997) Leuk Lymphoma 26: 99–105.
• Robak T, Blasinska-Morawiec M, Blonski J, Hellmann A, Halaburda K, Konopka L, Kotlarek-Haus S, Potoczek S, Hansz J, Dmoszynska A, et al. (1999) Eur J Haematol 62: 49–56.
• Rodriguez GI, Jones RE, Orenberg EK, Stoltz ML, Brooks DJ (2002) Clin Cancer Res 8: 2828–2834.
• Ross DD, Joneckis CC, Ordonez JV, Sisk AM, Wu RK, Hamburger AW, Nora RE (1989) Cancer Res 49: 3776– 3782.
• Saven A, Piro LD (1994) Ann Intern Med 120: 784–791.
• Seley KL (2000) Curr Opin Investig Drugs 1: 135–140.
• Skierski JS, Koronkiewicz M, Grieb P (1999) Cytometry 37: 302–307.
• Takahashi T, Nakashima A, Kanazawa J, Yamaguchi K, Akinaga S, Tamaoki T, Okabe M (1998) Cancer Chemother Pharmacol 41: 268–274.